Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
Metformin, Obesity, Abdominal, Diabetes Mellitus, Type 2
About this trial
This is an interventional treatment trial for Metformin focused on measuring Metformin, Glucagon-Like Peptide-1 Receptor, Obesity, Abdominal, Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease, Metabolism Disorder, Glucose
Eligibility Criteria
Inclusion Criteria: Aged 18-65 years old BMI≥24kg/㎡, or waist circumference: > 85cm (for male) or > 80cm (for female) Has been diagnosed with type 2 diabetes mellitus Good blood glucose control in recent three months: random blood sugar < 14mmol/L and HbA1c 6-9% Not received any drugs affecting glucose and lipid metabolism or weight loss surgery in the past one month Exclusion Criteria: Abnormal weight gain caused by other endocrine diseases Severe metabolic diseases, such as diabetic ketoacidosis, hypertonic hyperglycemia Type 1 diabetes or other special types of diabetes Used drugs affecting glycolipid metabolism in the past three months Severe bleeding tendency that unable to complete venous blood collection Patients with MRI contraindications Severe renal insufficiency or severe liver insufficiency Patients with advanced malignant tumors Serious cardiovascular and cerebrovascular diseases Rheumatic and immune diseases Pregnant and lactating women
Sites / Locations
- Ren Ji Hospital, Shanghai Jiao Tong University School of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Liraglutide group
Semaglutide group
Metformin group
Liraglutide is injected once a day.
Semaglutide is injected once a week.
Metformin is taken orally daily.